Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | RAD1 | O60671 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421304 | 1.00 | P2RY6 (0.42) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL28631538 | 0.79 | CYP3A4 (0.42) | CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL30298595 | 0.75 | ADRA2A (0.50) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL21518466 | 0.75 | ADRA2A (0.50) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL30298639 | 0.75 | ADRA2A (0.50) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL2780940 | 0.75 | ADRA2A (0.50) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL30298647 | 0.75 | P2RY6 (0.38) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL21597592 | 0.75 | P2RY6 (0.38) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL30406321 | 0.75 | TRPV4 (0.47) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL16014037 | 0.75 | TRPV4 (0.47) | P2RY6MIFCA1CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885CA1 4661/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885CA1 4661/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | P2RY6 1187/4885MIF 3660/4885CA1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.